SCHEMBL676083

SCHEMBL676083

CCOC(=O)Cc1csc(N[C]=O)n1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.64
GAA P10253 1/20 0.64
LMNA P02545 3/20 0.62
MAPK1 P28482 2/20 0.60
TSHR P16473 2/20 0.60
MAPT P10636 2/20 0.60
HTT P42858 1/20 0.60
ALDH1A1 P00352 4/20 0.60
POLB P06746 2/20 0.59
TP53 P04637 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
ESR2 Q92731 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11009364 0.84 SMN1; SMN2 (0.69) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL11376337 0.83 SMN1; SMN2 (0.67) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL6220893 0.82 MAPT (0.74) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL11368738 0.81 SMN1; SMN2 (0.72) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL676084 0.81 SMN1; SMN2 (0.64) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL1341401 0.80 SMN1; SMN2 (0.70) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL9660929 0.80 ALDH1A1 (0.70) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL1340139 0.80 SMN1; SMN2 (0.70) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL31527707 0.80 SMN1; SMN2 (0.63) SMN1; SMN2GAALMNAMAPK1TSHR
SCHEMBL11370116 0.80 LMNA (0.75) SMN1; SMN2GAALMNAMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 EP claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 WO claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2003043999-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP claimed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 SMN1; SMN2 3879/4885GAA 567/4885LMNA 3562/4885
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 SMN1; SMN2 2532/4885GAA 265/4885LMNA 1897/4885
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3226/4885GAA 387/4885LMNA 1833/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 SMN1; SMN2 3799/4885GAA 586/4885LMNA 3439/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 SMN1; SMN2 3179/4885GAA 351/4885LMNA 1976/4885
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 SMN1; SMN2 3179/4885GAA 351/4885LMNA 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.